ArticleUrology2024
National Long-term Survival Estimates After Radical Prostatectomy for Prostate Cancer.
Article in Urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 9 citations in OpenAlex.
- Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.Future oncology (London, England) · 2026Trial
- Unconventional T cells in urological cancers: catch them if you can.Nature reviews. Urology · 2026Review
- DVH parameters and gastrointestinal/genitourinary toxicities in moderate hypofractionated salvage radiotherapy after radical prostatectomy.Journal of radiation research · 2026Article
- Prognosis of patients with early salvage radiotherapy and low persisting or increasing PSA levels after radical prostatectomy for prostate cancer. A retrospective comparative analysis.Clinical and translational radiation oncology · 2026Article
- Copper isotope fractionation and copper-to-zinc ratios reveal altered metal homeostasis in prostate cancer.Scientific reports · 2026Article
- EMBARK in biochemically recurrent prostate cancer: a journey for some but not most.The oncologist · 2026Article
- The Impact of Different Dietary Patterns on Mortality and Prognosis After Non-Metastatic Prostate Cancer Diagnosis: A Systematic Review.Healthcare (Basel, Switzerland) · 2025Review
- Article
- Article
- Radical Prostatectomy in Kidney Transplant Recipients-A Multicenter Experience.European urology open science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo examine survival and disease control outcomes, including metastasis-related survival outcomes, in a large contemporary cohort of patients undergoing radical prostatectomy for localized prostate cancer.
methodsWe conducted a retrospective study of men with localized prostate cancer treated with radical prostatectomy from 2005 to 2015 with follow-up through 2019 in the Veterans Health Administration. We defined biochemical recurrence (BCR) as a prostate-specific antigen ≥0.2 ng/mL. We used a validated natural language processing encoded dataset to identify incident metastatic prostate cancer. We estimated overall survival from time of surgery, time of BCR, and time of first metastasis using the Kaplan-Meier method. We then estimated time from surgery to BCR, BCR to metastatic disease, and prostate-cancer-specific survival from various time points using cumulative incidence considering competing risk of death.
resultsOf 21,992 men undergoing radical prostatectomy, we identified 5951 (27%) who developed BCR. Of men with BCR, 677 (11%) developed metastases. We estimated the 10-year cumulative incidence of BCR and metastases after BCR were 28% and 20%, respectively. Median overall survival after BCR was 14years, with 10-year survival of 70%. From the time of metastasis, median overall survival approached 7years, with 10-year overall survival of 34%. Prostate cancer-specific survival for the entire cohort at 10years was 94%.
conclusionIn this large contemporary national cohort, survival for men with biochemically recurrent prostate cancer is longer than historical cohorts. When counseling patients and designing clinical studies, these updated estimates may serve as more reliable reflections of current outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.